**Research Article**

# Is the extent of surgical resection important in patient outcome in benign and borderline phyllodes tumors of the breast?

**Ali İbrahim SEVİNÇ[1],\*, Süleyman Özkan AKSOY[1], Merih GÜRAY DURAK[2], Pınar BALCI[3]**
[1]Department of Surgery, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
[2]Department of Pathology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
[3]Department of Radiology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey

**Background/aim:** Phyllodes tumors (PTs) of the breast are rare, and their diagnosis and treatment remain controversial. This retrospective study aims to examine the clinical outcome of benign and borderline PTs, according to the surgical margins.

**Materials and methods:** We examined the medical records of 122 patients in our clinic, who had histologically confirmed benign and borderline PTs between 1994 and 2017.

**Results:** The mean age of the patients was 40.6 years (range 18.0–81.0, ±12.1 standard deviation [SD]) and the mean tumor size was 25.8 mm (range 9–65, ±10.3 SD). All patients underwent a breast-conserving procedure and the median follow-up was 51 months. Tumor margins were positive (tumor touching the ink) in 43 patients (35%). Only 16 patients (13%) had margins ≥10 mm. The margins were between 2 and 10 mm in most patients (40%) and ≤1 mm in 12% of the patients.

**Conclusion:** Although no re-excision was performed to obtain grossly clear margins, local recurrence was not observed in any patients. Therefore, revision surgery for close or positive surgical margins for benign and borderline PTs should not be performed as a rule. As most tumors recur within 2 years of diagnosis, we propose a close clinical and imaging follow-up during this period.

**Key words:** Phyllodes tumor, surgery, surgical margins

## 1. Introduction

Phyllodes tumors (PTs) are rare fibroepithelial tumors of the breast that account for less than 1% of all primary breast tumors (1,2). They were first described by Johannes Muller in 1838 as "cystsarcoma phyllodes" (3). However, in 1982, the World Health Organization (WHO) declared a more suitable term of "phyllodes tumor", which has been widely accepted (4).

Benign PTs are more frequent, with an incidence of 35%–85%. Borderline PTs, on the other hand, account for 7%–40% of cases (5). Local recurrence rates vary in the literature, and are reported to be approximately 8% for benign PTs and 21% for borderline cases (6).

The macroscopic appearance of most PTs is that of a circumscribed, round to oval multinodular mass that lacks a true histologic capsule. Most PTs are indistinguishable from fibroadenomas (FAs) on gross examination. Histologically, PTs of the breast show the characteristic appearance of leaf-like architecture, increased stromal overgrowth, cellularity, atypia, and mitosis (7). According to the WHO, three histologic types are identified based on histopathological features: benign, borderline, and malignant (4).

Diagnosis of PTs with imaging methods is generally difficult and they are often confused with FAs. On mammography (MG), PTs have smooth, round-to-oval margins with lobulation. On ultrasonography (US), PTs are generally heterogeneous, well-defined, hypoechoic oval lesions surrounded by a capsule or pseudocapsule, and show lobulation. However, internal echoes and calcifications are absent (8).

Surgery is the main treatment for PTs of the breast. Nevertheless, the extent of initial resection and the necessity for re-excision to have adequate margins remain controversial. Both PTs and FAs are on the same morphological spectrum; hence, it can be very difficult to differentiate these entities clinically, radiologically, and in terms of tissue sampling. Patients usually undergo enucleation of this innocuous breast lump, the diagnosis of which results from PTs. The question regarding these

\* Correspondence: ibrahim.sevinc@deu.edu.tr

patients is whether or not to obtain wide excision margins to achieve local disease control and spare them the potential cosmetic and psychological problems that may arise with resurgery.

In this retrospective study, we aimed to investigate clinical outcomes of 122 benign and borderline PTs of the breast, treated and followed-up in a single institution, to better characterize both surgical management patterns and clinical behavior of these rare tumors, according to surgical margins at first resection.

## 2. Materials and methods

The medical records of 122 patients with histologically confirmed benign and borderline PTs operated on at our clinic between 1994 and 2017 were retrospectively reviewed. Informed consent was obtained from all patients during hospitalization.

The clinical data analyzed included patient demographics, radiologic methods used for diagnosis, tumor size, localization, and type of surgery. Histopathologic features of the tumor, as well as patient follow-up data and outcomes, were evaluated.

Preoperative MG and US were evaluated by our breast radiologist in the Department of Radiology, Dokuz Eylül University. All patients were evaluated according to the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS). Atlas (5th edition) was used in all imaging methods.

As PTs may be difficult to distinguish preoperatively from cellular FAs due to their heterogeneous nature, neither fine needle aspiration cytology (FNAC) nor core needle biopsy was performed as the initial management.

Operative treatment was defined as wide local excision (WLE), enucleation, or wire-guided surgery (WGS). Patients with palpable mass underwent WLE. WGS, which has abnormal radiologic findings without palpable mass, was used in patients. Enucleation of the tumor was performed in patients that had been diagnosed with FAs peroperatively.

All the histologic slides were examined by our breast pathologist in the Department of Pathology, Dokuz Eylül University. The tumors were classified according to the WHO classification of breast tumors. Data on tumor size and margins (negative or positive, and minimum tumor-free margin) were obtained.

We subdivided the tumors into 4 groups based on the nearest resection margins: (1) positive resection margin, (2) resection margin ≤ 1 mm, (3) resection margin between 2 mm and <10 mm, and (4) resection margin ≥ 10 mm.

Regular clinical and imaging follow-up of all the patients were similar during the first 2 years after surgery.

Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA) 20.0 was used for statistical analyses.

Categorical variables were expressed as percentages and continuous variables as means, median, standard deviation (SD), and range.

## 3. Results

### 3.1. Clinical characteristics

From 1994 to 2017, a total of 122 female patients with a mean age of 40.6 years (range 18.0–81.0, ±12.1 SD) were included in the study. The mean ages for benign and borderline PTs were 39.3 and 50.5 years, respectively. The characteristics of the patients are summarized in Table 1.

Most patients (90%) presented with palpable, mobile, and painless masses in their breasts. In 12 (10%) patients, the diagnosis was based on abnormal radiologic findings.

In 58 (47.5%) patients, the tumor was located in the right breast, and in 64 (52.5%), it was located in the left breast. All patients presented with a unilateral breast lump at diagnosis.

### 3.2. Imaging findings

MG was performed in 46 (37.7%) patients, of whom 33 (71.7%) were classified as suspicious (BI-RADS ≥ 4). In US imaging, this was performed in all patients, 105 (86.0%) of which were classified as suspicious (Table 1). PTs were suspected in 63 (51.6%) patients during imaging analyses.

### 3.3. Primary treatment

All patients underwent surgery. A total of 67 (55.0%) patients were treated with WLE, 43 (35.0%) with enucleation, and 12 (10.0%) with WGS (Table 2).

No patients underwent axillary lymph node dissection. Adjuvant therapy was not given.

### 3.4. Histopathologic features

The histopathologic characteristics of the cases are summarized in Table 2. One hundred and eight (88.5%) tumors were benign PTs and 14 (11.5%) were borderline on histopathological analyses. The mean tumor size was 25.8 mm (range 9–65, ±10.3 SD). Surgical margin data were available for all patients.

(1) 35% (n = 43) of patients had positive surgical margins after surgery (tumor touching the ink). All patients with positive margins had benign PTs.

(2) 12% (n = 14) of patients had margins ≤ 1 mm (close margins, but no tumor on ink).

(3) 40% (n = 49) of patients had margins between 2 and <10 mm.

(4) 13% (n = 16) of patients had margins ≥ 10 mm.

### 3.5. Follow-up

The median follow-up was 46 ± 57.6 months (range 0–277) in benign PTs and 133 ± 67.2 months (range 36–240) in borderline PTs (Table 2).

All 43 patients with positive margins had benign histology. Re-excision was not performed in these patients, who were closely followed-up by physical examination

**Table 1.** Patient and lesion characteristics (n = 122).

|  |  | Mean ± SD (range) | n (%) |
|---|---|---|---|
| Age mean (years) |  | 40.6 ± 12.1 (18–81) |  |
| Preoperative diagnostic modalities | By palpation |  | 110 (90) |
|  | By radiologic findings |  | 12 (10) |
| Mammographic impression (n = 46) | BI-RADS 3 |  | 13 (28.4) |
|  | BI-RADS 4a |  | 27 (58.6) |
|  | BI-RADS 4b |  | 4 (8.7) |
|  | BI-RADS 4c |  | 2 (4.3) |
| Echographic impression (n = 122) | BI-RADS 3 |  | 17 (13.9) |
|  | BI-RADS 4a |  | 99 (81.1) |
|  | BI-RADS 4b |  | 4 (3.3) |
|  | BI-RADS 4c |  | 2 (1.6) |
| Tumor laterality | Left |  | 64 (52.5) |
|  | Right |  | 58 (47.5) |

**Table 2.** Histopathological characteristics (n = 122).

|  |  | Benign (n = 108) | Borderline (n = 14) | Total (n = 122) |
|---|---|---|---|---|
| Size |  | 26.1 ± 10.6 | 23 ± 7.5 | 25.8 ± 10.3 |
| Mean ± SD (range) |  | (9–65) | (11–35) | (6–5) |
| Mitosis, n (%) | 0–4 | 108 (89) | 4 (3) | 112 (92) |
|  | 5–10 | - | 9 (7) | 9 (7) |
|  | >10 | - | 1 (1) | 1 (1) |
| Surgical margins, n (%) | Positive | 43 (35) | - | 43 (35) |
|  | ≤1 mm | 13 (11) | 1 (1) | 14 (12) |
|  | 2–<10 mm | 40 (33) | 9 (7) | 49 (40) |
|  | ≥10 mm | 12 (10) | 4 (3) | 16 (13) |
| Type of surgery, n (%) | Enucleation | 43 (35) | - | 43 (35) |
|  | Wide local excision | 55 (45) | 12 (10) | 67 (55) |
|  | Wire guided | 10 (8) | 2 (2) | 12 (10) |
| Follow-up (months) | Median | 46 ± 57.6 | 133 ± 67.2 | 51 ± 63.1 |
|  | Range | (0–277) | (36–240) | (0–277) |

and imaging methods. The median follow-up within this group of patients was 39 months (range 1–277). There was no local recurrence during the follow-up period.

## 4. Discussion
PTs of the breast are rare, representing <1% of all breast neoplasms (1,2). The WHO categorizes these tumors as benign, borderline, and malignant, based on histopathologic characteristics (4). Their prognosis and clinical outcome are still associated with much uncertainty and variability. In addition, malignant PTs commonly show more aggressive behavior, both locally and systemically, compared to their benign and borderline counterparts (9). In this study, we investigated benign and borderline PTs of the breast treated, diagnosed, and followed-up at our institution, to better characterize both surgical management patterns and the clinical behavior of these tumors.

PTs may occur at any age, with a mean age ranging between 30 and 52 years (10). In our study, all patients were female with a mean age of 40.6 years at diagnosis, which is similar to other series.

Painless palpable mobile mass in the breast was the most common presenting symptom in our series (90.0%). Tumor size ranged from 9 to 65 mm, with a mean size of 25.8 mm. In several studies in the literature, the size of PTs of the breast varies between 0.5 and 27 cm, with a mean between 5 and 7.2 cm (11). In contrast, the mean tumor size in our series seems to be considerably smaller.

PTs were localized in either breast in almost equal proportion (47.5% vs. 52.5%) in our study, similar to several other series (12).

The role of imaging is uncertain in diagnosis due to lack of specific characteristics. PTs and FAs have similar MG and US features (8). We performed US as the first-step imaging method in all patients in our study. MG was performed only in patients aged more than 40 years. Diagnosis of PTs was suspected in 63 (51.6%) patients during imaging analyses in our series, a ratio that was higher than that in the literature (13). WGS was performed on 12 (10%) patients who presented with abnormalities detected during imaging analyses without a palpable mass.

FNAC of the breast has low sensitivity (72.0%) to differentiate the type of histology (14,15). Moreover, false-negative results can be obtained when sampling is performed in an area of hypocellular stroma (11). Core needle biopsy is more acceptable than FNAC for obtaining a correct diagnosis, as it can provide specific histopathologic findings. However, its false negative rates are reported as high as 30.0% in the literature (16).

As PTs may be difficult to diagnose with cytologic and histologic methods preoperatively due to their heterogeneous nature, none was the preferred choice of first-line management in our institution. Instead, excisional biopsy was performed to achieve an accurate diagnosis with examination of the entire mass. This approach increased cost-effectiveness.

Surgery remains the cornerstone of treatment for PTs of the breast. However, due to their unpredictable clinical presentation, uncertain pathological behavior, and inaccurate preoperative diagnosis, there still seem to be dilemmas in their treatment plans (11). Enucleation of the tumor is frequently preferred, since the majority of these lesions are diagnosed as FAs preoperatively (15). The question in PT cases, however, is whether or not all these patients should undergo a second operation to provide adequate clear margins. In the literature, there is no consensus about the necessity of a surgical revision of margins in such cases.

Numerous clinical studies recommend wide excision of the tumor with a 10-mm clear margin (12,17–21), which causes major difficulties in achieving good cosmetic results. However, recent data show that there is no direct relationship between the margin status or width of negative margins and recurrence (22,23). Kim et al. have suggested that recurrence rates are very low for benign PTs, regardless of margin status, even for patients treated with local excision (24). In addition, Yom et al. have reported that margin status is not associated with risk of local recurrence (15). In their series of 164 PT cases, Jang et al. found that a 10-mm negative margin thickness did not confer any local control advantage over a narrower negative margin (22). Onkendi et al. have shown that the extent of surgical resection did not affect disease-free survival in patients with borderline and malignant PTs (23). In addition, there are certain series in the literature that report recurrence in PT cases with negative margins at initial surgery (12,17). In their largest series, Zurrida et al. advocated a wait-and-see policy for patients with benign and low-grade tumors and positive surgical margins, due to lower recurrence rates (25,26). In our series, we performed complete surgical resection with safe margins in clinically and radiologically suspected benign PTs or tumors of undetermined clinical significance.

In our study, 35% of patients had positive surgical margins and 12% had close margins of less than 1 mm. This might be explained by the fact that the majority of benign tumors were diagnosed peroperatively as FAs, and enucleation of the tumors were, therefore, performed. None of the patients underwent reoperation to increase the margin. In agreement with this, Tan et al. suggest a conservative approach to benign PTs that have initially been enucleated without margins, and excision with negative margins should be achieved for recurrent and malignant PTs (14). This is supported by the MD Anderson Cancer Center clinical practice algorithm for PTs, which recommends that if initial excision has a negative margin in benign PTs, further surgery is not required (15). Despite positive and very close margins (47.0%) in our study, we have no local recurrence, whereas local recurrence rates in other series vary from 8.0% to 13.0% (6,12,19,21). This may be explained by the fact that these studies do not separate benign or borderline PTs from high-grade malignant PTs in evaluation (12,22,27).

Several factors have been found to be related to local recurrence. Tumor size and mitotic activity were found to be independently associated with local recurrence, whereas margin status and surgical procedure were not. The risk of local recurrence is higher in larger tumors and tumors with >10 mitosis per 10 high power fields. In our series, mean tumor size was 25.8 mm and 121 (99.0%) patients had <10 mitosis per 10 high power fields. In agreement with our results, several authors have proposed that re-excision should be performed in tumors with high mitotic activity (15,20,21). Moreover, local recurrence of benign

and borderline tumors can be well managed by further surgery (either breast-conserving surgery or mastectomy).

PTs show unpredictable behavior of histotypes. Metastases are more common in malignant PTs. In a similar manner, we have no metastases in our series (17,21,22). Nevertheless, several authors have described local recurrence and even distant metastases of benign and borderline tumors (18,19,21,22).

In this study, the median follow-up was 46 months in benign and 133 months in borderline PTs. The mean duration of time-to-recurrence varies in the literature, but most tumors recur within 2 years from diagnosis (20,21,25–27). Therefore, it seems that most recurrences can be detected during this time frame with appropriate follow-up.

Our findings suggest that patients with benign and borderline PTs have a less aggressive disease course and low risk of local recurrence, irrespective of margin status. Reoperation with wider resection in healthy tissue is not justified in selected patients. There is no evidence-based recommendation for delineating an optimal length of follow-up or follow-up intervals. Nevertheless, beginning with clinical and radiological reviews at 6 months and continuing for the first 2 years after surgery, follow-up of yearly evaluation may be an appropriate practice suggestion.

Our study may lead to new perspectives in the surgical management of patients with benign or borderline PTs of the breast, enable patients feel good about their breast cosmesis, and prevent tumor recurrence efficiently.

However, our data have limited capacity for making firm assumptions, as this is a retrospective study. The results of prospective trials and similar studies are warranted to support our results.

## References

1. Dyer NH, Bridger JE, Taylor RS. Cystosarcoma phylloides. Br J Surg 1966; 53: 450-455.

2. Buchanan EB. Cystosarcoma phyllodes and its surgical management. Am Surg 1995; 61: 350-355.

3. Muller J. Uber den Feineren Ban und Die Formen der Krankaften Geschwulste. Vol. 1. Berlin, Germany: Greiner, 1838 (in German).

4. World Health Organization. The World Health Organization histological typing of breast tumors—second edition. Am J Clin Pathol 1982; 78: 806-816.

5. Cheng SP, Chang YC, Liu TP, Lee JJ, Tzen CY, Liu CL. Phylloides tumor of the breast: the challenge persists. World J Surg 2006; 30: 1414-1421.

6. Barth RJ Jr, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol 2009; 16: 2288-2294.

7. Tse GMK, Niu Y, Shi HJ. Phyllodes tumor of the breast: an update. Breast Cancer 2010; 17: 29-34.

8. Duman L, Gezer NS, Balcı P, Altay C, Başara I, Durak MG, Sevinç AI. Differentiation between phyllodes tumors and fibroadenomas based on mammographic sonographic and MRI features. Breast Care 2016; 11: 123-127.

9. August AD, Kearney T. Cystosarcoma phyllodes: mastectomy, lumpectomy, or lumpectomy plus irradiation. Surg Oncol 2000; 9: 49-52.

10. Jacklin RK, Ridgway PF, Ziprin P, Healy V, Hadjiminas D, Darzi A. Optimising preoperative diagnosis in phyllodes tumor of the breast. J Clin Pathol 2006; 59: 454-459.

11. Bhargav PR, Mishra A, Agarwal G, Agarwal A, Verma AK, Mishra SK. Phyllodes tumor of the breast: clinicopathological analyses of recurrent vs. non-recurrent cases. Asian J Surg 2009; 32: 224-228.

12. Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL, Liu TP. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol 2005; 91: 185-194.

13. Tan H, Zhang S, Liu H, Peng W, Li R, Gu Y, Wang X, Mao J, Shen X. Imaging findings in phyllodes tumors of the breast. Eur J Radiol 2012; 81: e62-69.

14. Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V et al. Phyllodes tumors of the breast: a consensus review. Histopathology 2016; 68: 5-21.

15. Yom CK, Han W, Kim SW, Park SY, Park IA, Noh DY. Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast. Ann Surg Oncol 2015; 22: 2912-2918.

16. Ward ST, Jewkes AJ, Jones BG, Chaudri S, Hejmadi RK, Ismail T, Hallissey MT. The sensitivity of needle core biopsy in combination with other investigations for the diagnosis of phyllodes tumors of the breast. Int J Surg 2012; 10: 527-531.

17. Guillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Lae M, Bollet M, Pierga JY, Salmon R, Fitoussi A. Management of phyllodes breast tumors. Breast J 2011; 17: 129-137.

18. Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PWT, Pollock RE, Hunt KK. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000; 89: 1502-1511.

19. Reinfuss M, Mitus J, Stelmach A, Rys J, Smolak K. The treatment and prognosis of patients with phyllodes tumor of the breast: an analyses of 170 cases. Cancer 1996; 77: 910-916.

20. Kapiris I, Nasiri N, A'Hern R, Healy V, Gui GP. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumors of the breast. Eur J Surg Oncol 2001; 27: 723-730.

21. Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, Susnik B, Giri D, Polo K, Patil S et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol 2007; 14: 2961-2970.

22. Jang JH, Choi MY, Lee SK, Kim S, Kim J, Lee J, Jung SP, Choe JH, Kim JH, Kim JS et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol 2012; 19: 2612-2617.

23. Onekendi EO, Jimenez RE, Spears GM, Harmsen WS, Ballman KV, Hieken TJ. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of the resection and tumor characteristics on patient outcome. Ann Surg Oncol 2014; 21: 3304-3309.

24. Kim S, Kim JY, Kim DH, Jung WH, Koo JS. Analyses of phyllodes tumor recurrence according to the histologic grade. Breast Cancer Res Treat 2013; 141: 353-363.

25. Zurrida S, Bartoli C, Galimberti V, de Palo G, Squicciarini P, Delledone V, Salvadori B, Veronesi P, Bono A. Which therapy for unexpected phyllode tumor of the breast? Eur J Cancer 1992; 28: 654-657.

26. Tan EY, Tan PH, Yong WS, Wong HB, Ho GH, Yeo AW, Wong CY. Recurrent phyllodes tumors of the breast: pathological features and clinical implications. ANZ J Surg 2006; 76: 476-480.

27. Taira N, Takabatake D, Aogi K, Ohsumi S, Takashima S, Nishimura R, Teramoto N. Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin. Jpn J Clin Oncol 2007; 37: 730-736.